Director — Derek DiRocco, Ph.D.: The resignation of a director is a departure event, but it is typically low materiality and neutral in direction unless accompanied by a dispute or high-level executive change.

Results of Operations and Financial Condition. On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purpo…

Entry into a Material Definitive Agreement. Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to which Tanabe had granted to the Company an exclusive, worldwide, royalty-free, sublicensable, perpetual and irrevocable license to certain intellectual property righ…

The Company did not incur any material early termination penalties in connection with the termination of the License Agreement. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 29, 2026 MINERALYS THERAPEUTICS, INC. By: /s/ Jeffrey A. Munsie Name: Jeffrey A. Munsie Title: Chief Legal Officer and Secretary

Director — Kristine Peterson, Lonnel Coats: The filing discloses the appointment of two new independent directors to expand the board, which is a routine governance action with no executive departure.

*** Forward Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to, the potential approval by the FDA of the lorundrostat NDA and the Company’s plans to commercially launch lorundrostat, the Company’s expectations with respect to finalizing an agreement with T…

Entry into a Material Definitive Agreement. Fourth Amendment to the License Agreement On June 2, 2026, Mineralys Therapeutics, Inc. (the “Company”) entered into a fourth amendment (the “Amendment”) to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025 (the “License Agreement”), between the Company and Tanabe Pharma Corporation (“Tanabe”) for the purposes of terminating the Company’s potential future royalty payments to Tanabe an…

Other Events. On June 3, 2026, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C. (the “Underwriters”), relating to the issuance and sale of 5,660,378 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The price in this offering is $26.50 per share. The Underwriters have agreed to purchase the shares f…

Results of Operations and Financial Condition. On May 6, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of…

Results of Operations and Financial Condition. On March 12, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “…

Results of Operations and Financial Condition. On November 10, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for p…

Other Events. On September 2, 2025, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 9,803,921 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The price to the publ…

Other Events. On September 2, 2025, Mineralys Therapeutics, Inc. (the “Company”) delivered written notice to BofA Securities, Inc. (“BofA”) and Evercore Group L.L.C. (“Evercore”), that it was suspending its use of and terminating the prospectus supplement, dated April 11, 2024, related to the Company’s common stock, $0.0001 par value per share, issuable pursuant to the terms of the ATM Equity Offering Sales Agreement, dated March 21, 2024, by and among the Company, BofA and Evercore (the “Sal…

Results of Operations and Financial Condition. On August 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes…

Results of Operations and Financial Condition. On May 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes o…

Other Events. On March 11, 2025, Mineralys Therapeutics, Inc. (“Mineralys” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 12,962,962 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The price to the public…

Results of Operations and Financial Condition. On February 12, 2025, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2024 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deeme…

Results of Operations and Financial Condition. On November 11, 2024, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for p…

Results of Operations and Financial Condition. On August 13, 2024, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes…

Director — Olivier Litzka, Ph.D.: Dr. Olivier Litzka resigned from the Board of Directors.

Other Events. As previously disclosed, in April 2023, Mineralys Therapeutics, Inc. (the Company) initiated its first pivotal trial, Advance-HTN, a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications in 261 adult subjects. Subj…

Results of Operations and Financial Condition. On May 9, 2024, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of…

Director — Alexander Asam, Ph.D.: Dr. Alexander Asam decided not to stand for re-election to the Board.

of such form that is considered “furnished” under the 1934 Act) (each such date, a “ Registration Statement Amendment Date ”), and (ii) Company Periodic Report Date, and (C) promptly after each reasonable request by the Agents (each date of any such request by the Agents, a “ Request Date ”), the Company will furnish or cause to be furnished to the Agents or, in the case of clause (A) above, the applicable Agent an officers’ certificate, dated such Settlement Date, such Registration Statement…

Unregistered Sales of Equity Securities. The disclosures set forth in